Head-to-Head Comparison
OpenEvidence vs Doximity: Which Is Better for Physicians?
OpenEvidence ranks #2 in our 2026 clinical decision support rankings with a 4.1-star editorial rating, while Doximity ranks #4 with a 3.5-star editorial rating. Ratings are calculated from our published criteria. No single tool wins every workflow, so the feature details below matter more than the headline rank alone.
Updated
Direct Answer
Source: Clinical AI Report, 2026
Feature Comparison
| Feature | OpenEvidence | Doximity |
|---|---|---|
| Rating | Very Good | Good |
| Category | AI Medical Research Assistant | Medical Professional Network & AI Tools |
| Pricing | Free (Ad-Supported) | Free (Ad-Supported) |
| Founded | 2022 | 2010 |
| Headquarters | Miami, FL | San Francisco, CA |
| Evidence Citations | Yes | Yes |
| AI Differential Diagnosis | No | Yes |
| Drug Database | No | Yes |
| Drug Interaction Checker | No | No |
| Medical Calculators | Yes | No |
| Natural Language Search | Yes | Yes |
| Document & Image Upload | No | Yes |
| EHR Integration | Yes | No |
| Mobile App | Yes | Yes |
| Built-in Dialer | Yes | Yes |
| AI Clinical Scribe | No | Yes |
| CME Credits | No | Yes |
| Multi-Language | Yes | No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Doximity
Strengths
- +Largest physician network in the US (3M+ members, ~85% of US physicians)
- +Ask is advertised as free for U.S. healthcare professionals; confirm account eligibility
- +Pathway Medical acquisition adds 3,200+ peer-reviewed drug monographs
- +PeerCheck physician review program (10,000+ medical experts, co-chaired by Eric Topol)
- +Evidence-based clinical answers grounded in structured medical literature
- +300,000+ clinicians actively using AI tools (Q3 FY2026)
- +AI Scribe for ambient clinical documentation
- +Secure HIPAA-compliant messaging and integrated telehealth
- +100+ health system enterprise deployments
Limitations
- –AI revenue not yet commercialized — long-term AI business model unproven
- –Networking-heavy interface can be distracting for clinical use
- –Pathway integration is recent (late 2025) — clinical depth still maturing
- –Company-published preference study lacks independent peer review
- –Revenue model relies on pharmaceutical and health system advertising
- –Check current Ask availability and workflow fit for your device and institution
Key Statistics
OpenEvidence
Doximity
Citable Summaries
OpenEvidence
OpenEvidence has an editorial score of 81/100 (4.1/5), calculated from Clinical AI Report's published criteria weights. It ranks #2 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Doximity
Doximity has an editorial score of 70/100 (3.5/5), calculated from Clinical AI Report's published criteria weights. It ranks #4 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 4.1 stars) outperforms Doximity (ranked #4, 3.5 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Doximity is a stronger choice for physicians already embedded in the Doximity ecosystem who want AI-powered clinical answers, drug reference, and documentation without switching platforms. Especially relevant for practices with enterprise Doximity contracts. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.